

## Donation of in-house developed product Yallaferon® and pandemic essentials to Mainland Hospitals

COVID-19 has exploded into a global pandemic since 2020. Mass movement of people during the Chinese New Year holiday in early stage of the epidemic had exacerbated the spread of COVID-19 across China. Yallaferon<sup>®</sup>, the in-house developed product of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or "the Group") has been selected as one of the critical materials for the epidemic prevention and control by the Department of Economic and Information Technology of Anhui Province. Despite the disruption of logistics and shortage of resources and manpower, Lee's Pharm has bearing its corporate social responsibility and donating pandemic essentials actively to save lives and support the preventive and control measures implemented by government.






Hefei manufacturing site of the Group has worked over-time to raise the production of Yallaferon<sup>®</sup> during Chinese New Year Holiday. Over RMB 5 million worth of critical materials in total (as of May 2021), including the Group products Yallaferon<sup>®</sup>, VSL#3<sup>®</sup> (Probiotics), Rasilez<sup>®</sup> (Aliskiren), imported gloves and surgical masks were donated to Mainland hospitals in Hubei, Anhui, Guangzhou Provinces etc. By providing the critical materials, the frontline healthcare workers could have adequate protection in the workplace while safeguarding the health of patients.





Lee's Pharm also donated Yallaferon® to those units in need through Anhui Red Cross Foundation.



With the exclusive technology, Yallaferon<sup>®</sup>, officially launched in China, 2001, is the only interferon  $\alpha 2b$  Gel that does not required refrigeration. It is convenient to carry and easy to absorb. Coronavirus can be transmitted mainly through close contact and droplets. Yallaferon<sup>®</sup> can be applied to the nostrils, mouth or skin surface to prevent viral infections.